Special Issue

Achromobacter spp: New Insights in Epidemiology, Pathogenicity, and Antimicrobial Therapy

Message from the Guest Editor

Achromobacter spp. are multidrug-resistant, non-fermenting Gram-negative bacilli increasingly being reported worldwide as opportunistic pathogens in patients with underlying conditions, especially cystic fibrosis (CF). The pathogenicity of these bacteria remains controversial among CF patients, and there are limited data concerning intrinsic or acquired resistance mechanisms and therapeutic options. Taxonomic studies describe a great diversity of species within the genus, with more than 20 species whose correct identification requires specific techniques not usually performed by the laboratories. The aim of this Special Issue is to expand the current knowledge on the role of *Achromobacter* spp. in human health: sources of contamination and pathogenicity of the various species for CF or non-CF patients, intrinsic and acquired resistance mechanisms, and therapeutic options, including new antibiotics. *Keywords: Achromobacter* spp.; epidemiology; identification; reservoirs; virulence; resistance; antimicrobial therapy

Guest Editor

Dr. Lucie Amoureux

Department of Bacteriology, University Hospital of Dijon, 21000 Dijon, France

Deadline for manuscript submissions

closed (30 December 2021)

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/74345

Microorganisms
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
microorganisms@mdpi.com

mdpi.com/journal/microorganisms

Microorganisms

an Open Access Journal by MDPI

Impact Factor 4.2
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/microorganisms

About the Journal

Message from the Editor-in-Chief

"Microorganism" merges the idea of the very small with the idea of the evolving reproducing organism is a unifying principle for the discipline of microbiology. Our journal recognizes the broadly diverse yet connected nature of microorganisms and provides an advanced publishing forum for original articles from scientists involved in high-quality basic and applied research on any prokaryotic or eukaryotic microorganism, and for research on the ecology, genomics and evolution of microbial communities as well as that exploring cultured microorganisms in the laboratory.

Editor-in-Chief

Dr. Nico Jehmlich
Department of Molecular Toxicology, UFZ-Helmholtz Centre for Environmental Research, 04318 Leipzig, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, PubAg, CAPlus / SciFinder, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Microbiology) / CiteScore - Q1 (Microbiology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.2 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

MDPI